Insulin resistance Medical Services in China

Insulin resistance is a pathophysiological condition in which cells—particularly in skeletal muscle, liver, and adipose tissue—fail to respond normally to insulin, resulting in impaired glucose uptake and utilization. As a compensatory mechanism, the pancreas secretes increasingly higher levels of insulin (hyperinsulinemia) to maintain euglycemia. Over time, this chronic demand may exhaust beta-cell function, leading to progressive hyperglycemia and ultimately type 2 diabetes mellitus (T2DM). The core pathogenesis involves defects in the insulin signaling cascade—including reduced tyrosine phosphorylation of insulin receptor substrate (IRS) proteins, aberrant activation of inflammatory pathways (e.g., JNK, IKKβ/NF-κB), mitochondrial dysfunction, endoplasmic reticulum stress, and lipotoxicity from ectopic fat deposition in liver and muscle. Adipose tissue inflammation and dysregulated adipokine secretion (e.g., elevated resistin, leptin resistance, reduced adiponectin) further exacerbate systemic insulin resistance.

Epidemiologically, insulin resistance is highly prevalent worldwide and underlies a broad spectrum of metabolic disorders. In China, population-based studies estimate that 25–35% of adults exhibit measurable insulin resistance—even among non-diabetic individuals—with prevalence rising sharply with age, urbanization, and sedentary lifestyles. It is a central feature of metabolic syndrome, affecting over 40% of adults with abdominal obesity or hypertension. Globally, insulin resistance contributes significantly to the burden of cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and chronic kidney disease.

Key modifiable risk factors include excess visceral adiposity, physical inactivity, high intake of refined carbohydrates and saturated fats, chronic sleep deprivation, and smoking. Non-modifiable determinants encompass genetic predisposition (e.g., variants in PPARG, TCF7L2, IRS1), ethnicity (higher susceptibility observed in East Asian, South Asian, and Hispanic populations), aging, and certain hormonal conditions (e.g., Cushing’s syndrome, acromegaly). Importantly, insulin resistance often develops silently for years before clinical manifestations emerge—making early detection via HOMA-IR, Matsuda index, or hyperinsulinemic-euglycemic clamp critical in high-risk cohorts.

The quality-of-life impact is substantial yet frequently underestimated. Patients commonly report fatigue, brain fog, increased hunger, and difficulty losing weight—symptoms that impair daily functioning, work productivity, and emotional well-being. Psychological distress—including anxiety and depression—is elevated due to diagnostic ambiguity, stigma around weight, and fear of progression to diabetes or cardiovascular events. Moreover, insulin resistance correlates strongly with reduced health-related quality of life (HRQoL) scores across physical, social, and mental domains, independent of BMI or glycemic status. Effective management therefore requires not only biomedical intervention but also behavioral support, nutritional counseling, and psychosocial care to sustain long-term adherence and improve holistic outcomes.

Insulin resistance is a pathophysiological state characterized by diminished cellular response to circulating insulin, resulting in impaired glucose uptake—particularly in skeletal muscle, adipose tissue, and the liver—and compensatory hyperinsulinemia. It represents a core defect in the development of type 2 diabetes mellitus (T2DM), metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), and cardiovascular disease. The etiology is multifactorial, involving complex interactions among genetic susceptibility, epigenetic modulation, chronic low-grade inflammation, mitochondrial dysfunction, endoplasmic reticulum (ER) stress, and dysregulated adipokine secretion.

Common causes include ectopic lipid accumulation—especially diacylglycerol (DAG) and ceramide deposition in muscle and hepatocytes—which activates serine/threonine kinases (e.g., PKC-θ, JNK, IKKβ) that phosphorylate insulin receptor substrate (IRS) proteins on inhibitory serine residues, thereby disrupting downstream PI3K-Akt signaling. Chronic hyperglycemia (glucotoxicity) and elevated free fatty acids (lipotoxicity) independently impair insulin signal transduction and promote beta-cell dysfunction. Additionally, adipose tissue dysfunction—manifested by hypertrophic adipocytes, macrophage infiltration, and altered secretion of adipokines (e.g., elevated resistin, leptin, and IL-6; reduced adiponectin)—exacerbates systemic inflammation and insulin resistance.

Triggers are often acute or subacute physiological or environmental stressors that unmask or accelerate underlying susceptibility. These include pregnancy (due to placental hormone-mediated antagonism of insulin action), acute illness or infection (via cytokine-mediated IRS-1 inhibition), prolonged glucocorticoid therapy (which induces hepatic gluconeogenesis and impairs GLUT4 translocation), rapid weight gain—particularly visceral adiposity—sleep deprivation (disrupting cortisol, growth hormone, and ghrelin/leptin balance), and sedentary behavior (reducing skeletal muscle glucose disposal capacity). Bariatric surgery-induced weight loss frequently reverses insulin resistance, underscoring the modifiable nature of many triggers.

Established risk factors encompass obesity—especially central/visceral adiposity—as excess adipose tissue releases proinflammatory cytokines and free fatty acids that impair insulin signaling. Age is an independent risk factor, with insulin sensitivity declining approximately 0.5–1% per year after age 20, partly due to sarcopenia, reduced physical activity, and mitochondrial aging. Physical inactivity reduces AMPK activation and GLUT4 expression, diminishing insulin-independent glucose uptake. Hypertension, dyslipidemia (elevated triglycerides, low HDL-C), and polycystic ovary syndrome (PCOS) are both comorbidities and markers of shared pathophysiology. Gestational diabetes history confers a 7-fold increased lifetime risk of T2DM, reflecting persistent beta-cell stress and residual insulin resistance.

Genetic factors contribute significantly: heritability estimates range from 40–70%. Polymorphisms in genes such as PPARG (Pro12Ala variant), TCF7L2 (strongly associated with impaired insulin secretion and peripheral resistance), IRS1 (Gly972Arg), AKT2, and GCKR influence insulin signaling, beta-cell function, and hepatic glucose metabolism. Epigenetic modifications—including DNA methylation at loci like ABCG1 and PHOSPHO1—induced by maternal undernutrition, gestational diabetes, or early-life overnutrition can program lifelong metabolic dysregulation. Monogenic forms (e.g., mutations in INSR causing type A insulin resistance or Rabson-Mendenhall syndrome) are rare but informative for mechanistic insights.

Environmental factors play a pivotal role. Diets high in refined carbohydrates, saturated and trans fats, and fructose (especially from sugar-sweetened beverages) promote hepatic de novo lipogenesis, oxidative stress, and gut dysbiosis—altering short-chain fatty acid production and intestinal barrier integrity (‘leaky gut’), thereby increasing endotoxin (LPS) translocation and systemic inflammation. Chronic exposure to environmental pollutants—including persistent organic pollutants (POPs), bisphenol A (BPA), and phthalates—acts as obesogens and endocrine disruptors, interfering with nuclear receptors (e.g., PPARγ, estrogen receptors) and promoting adipogenesis and insulin resistance. Urbanization-related factors—such as chronic psychosocial stress (elevating cortisol and catecholamines), circadian misalignment (e.g., shift work), and reduced green space exposure—further compound metabolic dysregulation through neuroendocrine and autonomic pathways.

Insulin resistance (IR) is a pathophysiological state characterized by diminished cellular response to circulating insulin, leading to compensatory hyperinsulinemia and, ultimately, progressive beta-cell dysfunction. It represents a core defect in the development of type 2 diabetes mellitus (T2DM), metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), and cardiovascular disease. As IR is largely asymptomatic in its earliest stages, clinical recognition relies on identifying subtle phenotypic clues, metabolic abnormalities, and associated comorbidities—particularly within the endocrinology setting.

Early symptoms are often nonspecific and easily overlooked. Patients may report persistent fatigue, especially postprandially, due to impaired glucose uptake into skeletal muscle and consequent energy substrate insufficiency at the cellular level. Mild cognitive complaints—such as 'brain fog,' reduced concentration, or delayed mental processing—may occur secondary to fluctuating cerebral glucose availability and neuroinflammatory changes linked to chronic hyperinsulinemia. Subtle weight gain, particularly central adiposity despite stable caloric intake, reflects adipose tissue expansion driven by insulin’s lipogenic effects and dysregulated adipokine secretion (e.g., elevated leptin, suppressed adiponectin). Some individuals experience increased hunger (polyphagia) and cravings for refined carbohydrates, attributable to rapid postprandial glucose excursions followed by reactive hypoglycemia—a consequence of exaggerated insulin secretion in response to glucose load. Sleep disturbances—including insomnia or unrefreshing sleep—may arise from sympathetic overactivity, nocturnal cortisol dysregulation, and associations with obstructive sleep apnea (OSA), which itself exacerbates IR.

Typical symptoms emerge as IR progresses and compensatory mechanisms falter. Acanthosis nigricans—a velvety, hyperpigmented, papillomatous dermatosis most commonly affecting the posterior neck, axillae, and groin—is a highly specific cutaneous marker of severe IR and hyperinsulinemia; it results from insulin-mediated stimulation of epidermal growth factor receptors. Hirsutism (excess terminal hair in androgen-sensitive areas), menstrual irregularities (oligo- or amenorrhea), and infertility in women strongly suggest IR-associated polycystic ovary syndrome (PCOS), where hyperinsulinemia augments ovarian androgen production and impairs folliculogenesis. In men, IR correlates with decreased libido, erectile dysfunction, and low serum testosterone—partly mediated by adipose-derived aromatase activity and hypothalamic-pituitary-gonadal axis suppression. Hypertension frequently manifests early, driven by insulin-induced sodium retention, sympathetic nervous system activation, and endothelial dysfunction. Patients may also note recurrent skin infections (e.g., candidiasis, boils), reflecting impaired neutrophil chemotaxis and phagocytosis under hyperglycemic/hyperinsulinemic conditions.

Accompanying symptoms reflect multisystem involvement. Dyslipidemia—characterized by elevated triglycerides, low HDL-C, and small dense LDL particles—is nearly universal and contributes to accelerated atherogenesis. Nonalcoholic steatohepatitis (NASH) may present with right upper quadrant discomfort, hepatomegaly, or elevated ALT/AST, though many remain asymptomatic until advanced fibrosis develops. Chronic low-grade inflammation may manifest as generalized arthralgias or myalgias. Patients often report mood lability, anxiety, or depressive symptoms, potentially linked to cytokine-mediated neuroinflammation, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and altered monoamine metabolism. Peripheral edema can occur secondary to renal sodium retention and microvascular permeability changes.

Complications arise from sustained metabolic stress and end-organ damage. The most consequential is progression to overt T2DM, typically after years of prediabetes (impaired fasting glucose or impaired glucose tolerance). Cardiovascular complications include coronary artery disease, myocardial infarction, stroke, and heart failure—mediated by endothelial injury, vascular smooth muscle proliferation, and prothrombotic states. Diabetic nephropathy may initiate silently with microalbuminuria before progressing to overt proteinuria and declining GFR. Retinopathy begins with microaneurysms and capillary dropout, risking vision loss. Neuropathy presents initially as distal symmetric sensory deficits (numbness, paresthesia, burning pain), while autonomic neuropathy may cause gastroparesis, orthostatic hypotension, or bladder dysfunction. NAFLD can advance to cirrhosis and hepatocellular carcinoma. IR also independently increases risk for obstructive sleep apnea, certain malignancies (e.g., endometrial, colorectal), and cognitive decline including Alzheimer’s disease ('type 3 diabetes').

Diagnosis relies on integrating clinical assessment with biochemical and functional testing. Fasting plasma glucose (FPG) and HbA1c identify dysglycemia but lack sensitivity for early IR. The gold-standard research tool is the hyperinsulinemic-euglycemic clamp, measuring glucose disposal rate (M-value) under steady-state insulin infusion; however, it is impractical for routine clinical use. More feasible indices include the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) = [fasting insulin (μU/mL) × fasting glucose (mmol/L)] / 22.5; values >2.5–3.0 suggest IR in non-diabetic adults. Quantitative insulin sensitivity check index (QUICKI) = 1 / [log(fasting insulin) + log(fasting glucose)] offers improved discrimination at lower insulin levels. Oral glucose tolerance test (OGTT) with concurrent insulin measurements reveals exaggerated insulin responses and delayed glucose clearance. Additional supportive markers include elevated triglycerides (>1.7 mmol/L), low HDL-C (<1.0 mmol/L in men, <1.3 mmol/L in women), waist circumference ≥102 cm (men) or ≥88 cm (women), and elevated hs-CRP (>3 mg/L).

Differential diagnosis must exclude conditions mimicking IR or causing secondary insulin resistance. Endogenous hypercortisolism (Cushing syndrome) presents with central obesity, purple striae, hypertension, and glucose intolerance—but distinguished by elevated late-night salivary cortisol, abnormal dexamethasone suppression, and characteristic imaging findings. Acromegaly causes insulin resistance via excess growth hormone antagonism of insulin signaling; confirmed by elevated IGF-1 and failure of GH suppression during OGTT. Lipodystrophies (congenital or acquired) feature severe IR with partial or complete absence of adipose tissue, low leptin, and marked hypertriglyceridemia. Hemochromatosis may induce IR through iron-mediated pancreatic beta-cell toxicity and hepatic dysfunction; diagnosed by elevated ferritin, transferrin saturation, and HFE gene mutations. Medications—including glucocorticoids, antipsychotics (e.g., olanzapine), protease inhibitors, and thiazide diuretics—can induce iatrogenic IR. Rare genetic syndromes (e.g., Rabson-Mendenhall syndrome, type A insulin resistance) present with severe IR, acanthosis nigricans, and ovarian hyperandrogenism in young patients, often with identifiable INSR gene mutations. Finally, chronic inflammatory states (e.g., rheumatoid arthritis, HIV) and advanced chronic kidney disease must be considered, as systemic inflammation and uremic toxins impair insulin signaling pathways.

Insulin resistance (IR) is a pathophysiological condition characterized by diminished cellular response to insulin, leading to compensatory hyperinsulinemia and, over time, progressive beta-cell dysfunction. It underlies metabolic syndrome, prediabetes, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and cardiovascular disease. Management in the Department of Endocrinology requires a stratified, evidence-based, and patient-centered approach integrating conservative, pharmacologic, and—rarely—surgical interventions.

Conservative treatment constitutes the cornerstone of IR management and must be initiated at diagnosis, regardless of glycemic status. Lifestyle modification remains the most effective first-line strategy, supported by robust clinical trial data including the Diabetes Prevention Program (DPP) and Finnish Diabetes Prevention Study. Structured medical nutrition therapy emphasizes caloric restriction (5–10% weight loss target), low-glycemic-index carbohydrates, increased dietary fiber (≥25 g/day for women, ≥38 g/day for men), moderate unsaturated fat intake, and strict limitation of added sugars and refined grains. Physical activity prescriptions include ≥150 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) combined with resistance training twice weekly to enhance skeletal muscle glucose uptake via GLUT4 translocation. Behavioral interventions—such as cognitive behavioral therapy (CBT), motivational interviewing, and digital health coaching—are increasingly integrated into outpatient endocrine care to improve adherence and sustain long-term behavior change. Sleep hygiene optimization (7–9 hours/night) and stress reduction (e.g., mindfulness-based stress reduction) are also clinically relevant, given the bidirectional relationship between cortisol dysregulation, adipose tissue inflammation, and IR.

Pharmacotherapy is indicated when lifestyle interventions fail to achieve metabolic targets (e.g., HbA1c ≥5.7%, fasting insulin >15 μU/mL, or persistent dyslipidemia/hypertension) or when comorbidities such as NAFLD, PCOS, or established T2DM coexist. Metformin remains the first-line pharmacologic agent: it activates AMP-activated protein kinase (AMPK), suppresses hepatic gluconeogenesis, improves peripheral insulin sensitivity, and demonstrates cardiovascular safety. Dosing typically begins at 500 mg once daily with meals, titrated to 1,000 mg twice daily based on tolerability and renal function (eGFR ≥45 mL/min/1.73m²). Thiazolidinediones (TZDs), particularly pioglitazone 15–45 mg daily, exert potent PPAR-γ–mediated effects on adipocyte differentiation and adiponectin upregulation; however, their use is limited by fluid retention, weight gain, fracture risk, and contraindication in NYHA Class III–IV heart failure. GLP-1 receptor agonists (e.g., semaglutide 0.25–2.0 mg weekly, dulaglutide 1.5 mg weekly) offer dual benefits: weight loss (mean 5–15% body weight), improved insulin sensitivity via central appetite suppression and delayed gastric emptying, and proven cardiorenal protection. SGLT2 inhibitors (e.g., dapagliflozin 10 mg daily) reduce glucotoxicity and promote mild natriuresis, indirectly ameliorating IR through improved ectopic fat deposition and endothelial function. Emerging agents—including dual GIP/GLP-1 receptor agonists (tirzepatide) and selective thyroid hormone receptor-β agonists (resmetirom, recently approved for NASH)—show promising insulin-sensitizing effects in phase III trials.

Surgical treatment is reserved exclusively for individuals with severe obesity (BMI ≥35 kg/m²) and confirmed, refractory IR despite ≥6 months of intensive multidisciplinary conservative and pharmacologic management. Bariatric/metabolic surgery—including Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and biliopancreatic diversion with duodenal switch (BPD/DS)—induces rapid, durable improvements in insulin sensitivity independent of weight loss, mediated by altered gut hormone secretion (increased GLP-1, PYY; decreased ghrelin), bile acid metabolism, and microbiome composition. RYGB demonstrates the highest rates of diabetes remission (60–80% at 2 years), while SG offers lower perioperative risk. Surgery requires rigorous preoperative evaluation (endocrine, nutritional, psychiatric, cardiac), lifelong postoperative monitoring (vitamin B12, iron, calcium, vitamin D), and ongoing behavioral support. It is not indicated for lean IR or isolated hyperinsulinemia without obesity-related comorbidity.

Treatment advantages in China reflect unique healthcare infrastructure, research investment, and population-specific innovations. China’s national tiered healthcare system enables seamless referral from community health centers to tertiary endocrine hospitals, facilitating early IR detection via standardized screening protocols (e.g., HOMA-IR calculation in routine physical exams). The National Center for Metabolic Diseases has established over 200 standardized IR management centers nationwide, integrating AI-driven risk prediction models trained on Chinese cohort data (e.g., China Kadoorie Biobank). Traditional Chinese Medicine (TCM) adjuncts—such as berberine (a natural AMPK activator with efficacy comparable to metformin in head-to-head RCTs) and acupuncture protocols targeting ST36 and SP6 points—are widely incorporated under evidence-based guidelines issued by the Chinese Endocrine Society. Moreover, China leads global adoption of continuous glucose monitoring (CGM) in primary care, enabling real-time assessment of glycemic variability—a sensitive surrogate of IR—and personalized feedback loops. Cost-effectiveness is enhanced by domestic generic drug manufacturing and government price controls, making metformin, GLP-1 RAs, and CGM systems significantly more accessible than in many high-income countries.

Recovery and long-term maintenance require proactive, longitudinal engagement. Patients should undergo quarterly HbA1c, fasting glucose, insulin, lipid panel, and liver enzyme assessments; annual oral glucose tolerance tests (OGTT) with insulin assays if indicated; and periodic abdominal ultrasound or FibroScan® for NAFLD surveillance. Weight maintenance—rather than further loss—is the priority after initial 5–10% reduction, emphasizing habit sustainability over restrictive diets. Patients are advised to monitor home blood pressure and perform self-reported symptom diaries (fatigue, acanthosis nigricans, menstrual irregularity) to detect early decompensation. Psychosocial support—including peer-led IR education groups and telehealth endocrinology follow-up—is strongly encouraged to mitigate stigma and reinforce agency. Finally, family-level intervention is critical: household dietary restructuring and shared physical activity goals significantly improve adherence and intergenerational metabolic health outcomes.